Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Autor:	Bang, Y-J, Bendell, J, Chao, Y, Chen, J-S, Chung, H C, Davis, S L, Dev, A, Gane, E, George, B, He, A R, Hochster, H *, Hsu, C-H, Ikeda, M, Lee, J, Lee, M, Mahipal, A, Manji, G, Morimoto, M, Numata, K, Pishvaian, M *, Qin, S, Ryan, D, Ryoo, B-Y, Sasahira, N, Stein, S, Strickler, J, Tebbutt, N, Lee, Michael S, Ryoo, Baek-Yeol, Hsu, Chih-Hung, Numata, Kazushi, Stein, Stacey, Verret, Wendy, Hack, Stephen P, Spahn, Jessica, Liu, Bo, Abdullah, Heba, Wang, Yulei, He, Aiwu Ruth, Lee, Kyung-Hun *
Zdroj:	In The Lancet Oncology June 2020 21(6):808-820
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu